Latest News and Press Releases

Curium has established a legal entity in China which represents a major milestone in Curium’s international growth strategy and will enhance Curium’s ability to serve patients with cancer across...

Curium and CapVest have announced the recapitalization of Curium via a new Continuation Vehicle The transaction values Curium at circa $7 billion, representing the largest transaction in nuclear...

Curium has entered a partnership with the Czech company ÚJV Řež, a leading expert in the development and production of radiopharmaceuticals, to manufacture diagnostic radiopharmaceuticals for patients...

Curium Biopharma will continue to lead discovery and new product development Strategic move aims to accelerate biopharma innovation and revolutionize the diagnosis and treatment of cancerCurium...

PARIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Curium Group announced today that together with PeptiDream Inc. and PDRadiopharma Inc., a registrational Phase 2 clinical trial has been initiated in Japan...

Curium will shortly open a new facility to manufacture cutting-edge diagnosis technology for diseases like cancer at the Churchill Hospital site, part of Oxford University Hospitals NHS Foundation...

Newcastle University has entered into a lease agreement with Curium for a new site dedicated to the manufacture of cutting-edge diagnostic technologies for diseases such as cancer. The facility will...

PETTEN, The Netherlands, May 21, 2025 (GLOBE NEWSWIRE) -- NRG PALLAS and Curium have extended their collaboration to produce molybdenum-99 through a new multi-year agreement. Molybdenum-99, which...

Swissmedic grants marketing authorization for PYLCLARI® in Switzerland b.e. Imaging is marketing authorization holder and has exclusive distribution rights for PYLCLARI® across Switzerland ZURICH,...

The acquisition of Nucleis will: Enhance Curium’s PET manufacturing capacity and radiopharmaceutical distribution network of 32 PET sites in Western EuropeImprove reliability and accessibility...